Authors : V Arunadevi, S N S Minnalkodi
DOI : 10.18231/j.ijogr.2020.075
Volume : 7
Issue : 3
Year : 2020
Page No : 348-351
Background: One of the chronic disabling illness affecting approximately 10% of women in midst of their
reproductive period is Endometriosis. The treatment goal of endometriosis is to activate decidualization
within the hormonally dependent ectopic endometrium and is regularly given to alleviate pain symptoms
and reduce its recurrence among women.
Objectives: The aim of the study was to evaluate the effectiveness of dienogest in reducing pain and its
influence on (QOL) quality of life among women affected with endometriosis.
Materials and Methods: A prospective observational cohort study was conducted at Karpaga Vinayaga
Institute of Medical Sciences and Research Centre including fifty patients with endometriosis treated with
dienogest two mg per day for three months.We assessed the pelvic pain symptoms by visual analogue scale
and (QOL)quality of life was determined by physical and mental index before and after 3 months of use of
dienogest.
Study Design: To perform statistical analysis, we used paired t test.
Results: Women were on average 33.18 + 4.43 years. The mean +SD of VAS of 7.72 (0.73) in women
with endometriosis was progressively decreased to 4.34(0.66) after 3 months of treatment with dienogest.
The physical index score values increased significantly from 31.94 to 42.77 (p<0>
increased from 35.07 to 45.86 (p<0>
acne, hot flushes and weight gain.
Conclusion: The results suggest that among women with endometriosis, dienogest has a relatively
favorable safety profile and is well accepted in bettering the quality of life (QOL).
Keywords: Endometriosis, (QOL) Quality of life, Dienogest, Pelvic pain.